Artelo Competitors

Delisted . USA . 
Stock . Artelo Biosciences
ARTLWDelisted Stock  USD 0.01  0.00  0.00%   
Artelo Biosciences competes with Arrowhead Pharmaceuticals, Krystal Biotech, BioNTech, Moderna, and Ascletis Pharma; as well as few others. The company classifies itself under Pharmaceuticals sector and is part of Health Care industry. Analyzing Artelo Biosciences competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Artelo Biosciences to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Artelo Biosciences competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.010.010.01
Details
Intrinsic
Valuation
LowRealHigh
0.010.010.01
Details

Artelo Biosciences Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Artelo Biosciences and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Artelo and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Artelo Biosciences does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
ADILW
+ 0.8
MRNA
AKESF
+ 0.78
BNTX
AVXT
+ 0.73
MRNA
BCDAW
+ 0.71
MRNA
AVXT
+ 0.69
EYEN
KRYS
+ 0.68
ARWR
  
High negative correlations   
AKESF
- 0.79
ARWR
BNTX
- 0.76
ARWR
ADILW
- 0.69
AKESF
AKESF
- 0.67
MRNA
AKESF
- 0.62
KRYS
ADILW
- 0.48
BNTX

Risk-Adjusted Indicators

There is a big difference between Artelo Stock performing well and Artelo Biosciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Artelo Biosciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
EYEN  6.29 (2.08) 0.00 (0.64) 0.00 
 0.00 
 11.76 
(19.18)
 92.81 
ARWR  2.18 (0.59) 0.00 (0.22) 0.00 
 0.00 
 4.67 
(3.86)
 19.44 
KRYS  1.82 (0.22) 0.00 (0.02) 0.00 
 0.00 
 4.45 
(3.75)
 12.05 
BNTX  2.34  0.40  0.16  0.48  2.25 
(2.75)
 5.96 
(3.90)
 24.81 
MRNA  2.42 (0.99) 0.00 (1.35) 0.00 
 0.00 
 5.10 
(6.86)
 17.47 
AKESF  3.98  0.86  0.12 (6.26) 3.85 
(7.36)
 12.00 
(7.89)
 41.83 
ADYX  6.52  0.64  0.00  0.29  0.00 
 0.00 
 0.00 
 0.00 
 266.67 
AVXT  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
BCDAW  17.63  1.62  0.06  3.01  18.27 
(28.05)
 57.25 
(40.00)
 139.50 
ADILW  25.83  4.02  0.11 (3.95) 25.95 
(39.21)
 95.66 
(55.00)
 199.49 
All Fundamental Data

Artelo Biosciences Competitive Analysis

The better you understand Artelo Biosciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Artelo Biosciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Artelo Biosciences' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ARTLW EYEN ARWR KRYS BNTX MRNA AKESF ADYX ADILW ASCLF
 0.00 
 0.01 
Artelo
 19.18 
 0.09 
Eyenovia
 1.35 
 18.79 
Arrowhead
 2.18 
 194.56 
Krystal
 6.74 
 120.76 
BioNTech
 6.20 
 43.66 
Moderna
 6.15 
 8.80 
Akeso,
 0.00 
 0.0001 
Adynxx
 52.50 
 0.01 
Adial
 0.00 
 0.18 
Ascletis
Market Volatility
(90 Days Market Risk)
Very steady
Dangerous
Very steady
Very steady
Very steady
Very steady
Unstable
Very steady
Very steady
Out of control
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
Good
Very Weak
OK
Very Weak
Very Weak
OK
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Very High
Low
Very Low
Very Low
Low
Unknown
Dangerous
Dangerous
Above Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Over Valued
Under Valued
Under Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Strong Buy
Strong Buy
Strong Buy
Buy
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Cautious Hold
Hold
Strong Hold
Strong Sell
Strong Sell
Not Rated
Not Rated
Strong Sell
Current Ratio
0.41
2.14
3.37
12.45
5.15
2.1
0.18
N/A
28.93
Net Asset
20.42 M
28.78 M
765.55 M
818.36 M
23.01 B
18.43 B
9.68 M
5.73 M
2.83 B
Profit Margin
N/A
N/A
N/A
0.22
-0.15
-0.44
N/A
N/A
-2.24
EBITDA
(10.29 M)
(24.11 M)
(175.67 M)
17.9 M
1.09 B
(3.28 B)
(3.42 M)
(13.78 M)
(169.35 M)
Operating Margin
N/A
-516.61
-27.85
0.42
0.0168
-0.0376
N/A
N/A
-3.11
Current Valuation
N/A
13.51 M
1.99 B
5.01 B
9.89 B
11.29 B
9.24 M
N/A
116.15 M
Price To Book
N/A
2.5
6.97
6.32
1.36
1.41
N/A
N/A
1.58
Retained Earnings
(31.02 M)
(145.49 M)
(1.03 B)
(269.83 M)
19.76 B
13.61 B
(36.2 M)
(63.67 M)
N/A
Current Asset
N/A
6.23 M
90.5 M
2.05 M
284.67 M
850 K
4.04 M
N/A
N/A
Beta
1.25
1.76
0.93
0.82
0.26
1.69
2.35
N/A
0.81
Number Of Employees
5
57
525
229
6.13 K
5.6 K
6
N/A
315
Shares Outstanding
2.33 M
86.44 M
124.31 M
28.76 M
239.74 M
384.82 M
5.81 M
N/A
1.09 B
Cash Flow From Operations
(8.01 M)
(23.84 M)
(153.89 M)
(88.8 M)
5.37 B
(3.12 B)
(6.02 M)
(11.19 M)
(146.93 M)
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
3.0
N/A
N/A
Total Debt
63 K
16.08 M
115.17 M
8.09 M
219.1 M
1.24 B
10.09 M
207.38 K
2.75 M
Return On Equity
-0.71
-9.15
-1.52
0.0638
-0.024
-0.18
N/A
N/A
-0.0632
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
-4.2
-22.86
N/A
Return On Asset
-0.44
-0.93
-0.41
0.0458
-0.0124
-0.0955
-1.92
N/A
-0.053
Number Of Shares Shorted
339
2.14 M
9.39 M
3.45 M
2.02 M
34.38 M
25.82 K
506
N/A
Book Value Per Share
-0.35
0.2
2.66
30.81
79.73
30.98
-1.9
N/A
2.5
Current Liabilities
N/A
904.7 K
25.64 M
40.74 K
143.37 M
2.44 M
3.43 M
N/A
N/A
Total Asset
20.42 M
28.78 M
765.55 M
818.36 M
23.01 B
18.43 B
9.68 M
5.73 M
2.83 B
Debt To Equity
N/A
0.31
0.17
0.016
0.014
0.07
-1.48
N/A
0.001
Short Ratio
N/A
2.45
9.41
23.12
3.0
7.59
2.86
N/A
N/A
Target Price
N/A
3.5
47.29
207.78
129.15
77.55
2.8
N/A
N/A
Shares Owned By Institutions
N/A
13.73
79.7
87.7
20.64
71.6
0.011
N/A
1.94
Market Capitalization
13.07 K
7.68 M
2.34 B
5.6 B
28.95 B
16.8 B
87.12 K
N/A
672.93 M
Price To Earning
N/A
-1.4
482.39
-6.36
5.19
6.37
-103.05
N/A
N/A
Price To Earnings To Growth
N/A
N/A
-1.32
N/A
0.0449
N/A
N/A
N/A
N/A
Price To Sales
N/A
244.7
118.89
23.17
9.52
3.31
0.0926
N/A
7.61
Net Income
(10.08 M)
(27.26 M)
(209.28 M)
10.93 M
1.19 B
(4.71 B)
(5.99 M)
(12.73 M)
(199.02 M)
Earnings Per Share
-1.43
-0.69
-4.65
1.77
-2.04
-5.81
-1.82
N/A
-0.027
Shares Owned By Insiders
N/A
9.99
4.46
12.3
62.3
9.52
N/A
N/A
67.02
Revenue
N/A
3.79 K
240.74 M
50.7 M
3.82 B
6.85 B
2.22 M
N/A
76.88 M
Working Capital
9.69 M
11.18 M
110.03 M
554.82 M
17.46 B
7.31 B
609.79 K
2.99 M
N/A
Cash And Equivalents
457.33 K
21.51 M
416.5 M
425.56 M
9.33 B
8.35 B
331 K
N/A
2.5 B
Cash Per Share
0.23
0.63
3.93
16.58
38.3
21.73
0.06
N/A
2.28
Gross Profit
N/A
12.4 M
240.74 M
N/A
16.07 B
10.55 B
N/A
N/A
39.17 M
Day Typical Price
0.0056
0.0888
19.12
195.2
118.44
44.26
8.8
1.0E-4
0.0045
0.18
Accumulation Distribution
N/A
0.2
0.0559
0.0229
0.0633
0.0745
N/A
N/A
0.79
N/A
Market Facilitation Index
N/A
0.0194
1.11
4.53
7.67
3.45
N/A
N/A
0.0048
N/A
Daily Balance Of Power
0.0
(1.09)
0.2252
0.9183
0.9948
0.7391
9.2 T
0.0
0.4375
0.0
Period Momentum Indicator
N/A
(0.02)
0.25
4.16
7.63
2.55
0.51
N/A
0.0021
N/A
Rate Of Daily Change
1.0
0.81
1.01
1.02
1.07
1.06
1.06
1.0
1.53
1.0
Day Median Price
0.0056
0.0887
19.29
195.52
117.28
44.56
8.8
1.0E-4
0.0037
0.18
Price Action Indicator
N/A
(0.01)
(0.37)
1.13
7.3
0.38
0.26
N/A
0.0035
N/A
Coefficient Of Variation
1165.88
(664.66)
(803.73)
(10,442)
679.58
(386.91)
810.58
2609.92
1005.85
1076.69
Mean Deviation
23.23
6.29
2.18
1.82
2.34
2.42
3.98
6.52
25.83
1.26
Jensen Alpha
2.91
(2.08)
(0.59)
(0.22)
0.3989
(0.99)
0.8565
0.6364
4.02
0.2881
Total Risk Alpha
(2.24)
(3.56)
(0.85)
(0.42)
(0.04)
(1.45)
(0.23)
(3.34)
(2.21)
(0.24)
Sortino Ratio
0.0854
N/A
N/A
N/A
0.1568
N/A
0.1159
N/A
0.1106
N/A
Downside Variance
943.59
N/A
N/A
N/A
6.92
N/A
38.81
N/A
1171.09
N/A
Standard Deviation
32.07
11.61
3.0
2.48
3.68
3.47
6.89
28.52
39.35
3.66
Kurtosis
0.8136
18.8
4.32
1.35
7.23
1.65
7.63
41.58
1.52
15.77
Potential Upside
68.38
11.76
4.67
4.45
5.96
5.1
12.0
N/A
95.66
N/A
Treynor Ratio
(1.93)
(0.64)
(0.22)
(0.02)
0.4766
(1.35)
(6.26)
0.2877
(3.95)
0.9328
Maximum Drawdown
147.53
92.81
19.44
12.05
24.81
17.47
41.83
266.67
199.49
33.04
Variance
1028.28
134.78
8.99
6.15
13.52
12.07
47.53
813.6
1548.52
13.4
Market Risk Adjusted Performance
(1.92)
(0.63)
(0.21)
(0.01)
0.4866
(1.34)
(6.25)
0.2977
(3.94)
0.9428
Risk Adjusted Performance
0.0753
(0.11)
(0.09)
(0.0004)
0.1204
(0.19)
0.1032
0.039
0.0858
0.0789
Skewness
0.7746
(3.18)
(0.80)
0.771
1.83
(0.29)
1.9
5.38
0.9495
1.98
Semi Deviation
23.45
N/A
N/A
N/A
2.25
N/A
3.85
N/A
25.95
N/A
Information Ratio
0.0818
(0.16)
(0.17)
(0.06)
0.1122
(0.30)
0.1047
0.0338
0.0961
0.0577
Value At Risk
(41.25)
(19.18)
(3.86)
(3.75)
(3.90)
(6.86)
(7.89)
N/A
(55.00)
N/A
Expected Short fall
(24.76)
N/A
N/A
N/A
(2.75)
N/A
(7.36)
N/A
(39.21)
N/A
Downside Deviation
30.72
N/A
N/A
N/A
2.63
N/A
6.23
N/A
34.22
N/A
Semi Variance
549.77
N/A
N/A
N/A
5.07
N/A
14.82
N/A
673.3
N/A

Artelo Biosciences Competition Performance Charts

Five steps to successful analysis of Artelo Biosciences Competition

Artelo Biosciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Artelo Biosciences in relation to its competition. Artelo Biosciences' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Artelo Biosciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Artelo Biosciences' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Artelo Biosciences, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Artelo Biosciences position

In addition to having Artelo Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Wireless Thematic Idea Now

Wireless
Wireless Theme
Companies providing wireless technology and communication services. The Wireless theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Wireless Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Other Consideration for investing in Artelo Stock

If you are still planning to invest in Artelo Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Artelo Biosciences' history and understand the potential risks before investing.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Transaction History
View history of all your transactions and understand their impact on performance
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY